

REF. DOCTOR: SELF



PATIENT NAME: ROSHANI MEENA

CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO : **0251WC001794**

PATIENT ID : ROSHF190393251 CLIENT PATIENT ID: 012303190031

ABHA NO :

AGE/SEX :30 Years Female
DRAWN :19/03/2023 09:54:00
RECEIVED :19/03/2023 12:04:44
REPORTED :26/03/2023 13:28:35

Test Report Status Final Results Biological Reference Interval Units

н	AEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECKUP BE	LOW 40FEMALE		
BLOOD COUNTS,EDTA WHOLE BLOOD			
HEMOGLOBIN (HB) METHOD: CYANIDE FREE DETERMINATION	12.1	12.0 - 15.0	g/dL
RED BLOOD CELL (RBC) COUNT METHOD: ELECTRICAL IMPEDANCE	4.16	3.8 - 4.8	mil/μL
WHITE BLOOD CELL (WBC) COUNT METHOD: ELECTRICAL IMPEDANCE	4.30	4.0 - 10.0	thou/µL
PLATELET COUNT METHOD: ELECTRONIC IMPEDANCE	164	150 - 410	thou/μL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV) METHOD: CALCULATED PARAMETER	36.1	36 - 46	%
MEAN CORPUSCULAR VOLUME (MCV) METHOD: CALCULATED PARAMETER	87.0	83 - 101	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD: CALCULATED PARAMETER	29.0	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD: CALCULATED PARAMETER	33.4	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD: CALCULATED PARAMETER	14.5 High	11.6 - 14.0	%
MENTZER INDEX	20.9		
MEAN PLATELET VOLUME (MPV) METHOD: CALCULATED PARAMETER	11.5 High	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT	F.6	4000	0/
NEUTROPHILS METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	56	40 - 80	%
LYMPHOCYTES METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	36	20 - 40	%
MONOCYTES METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	07	2 - 10	%
EOSINOPHILS METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	01	1 - 6	%

Dr. Akansha Jain Consultant Pathologist





Page 1 Of 15

View Report







CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WC001794 PATIENT ID : ROSHF190393251

CLIENT PATIENT ID: 012303190031

ABHA NO

AGE/SEX :30 Years Female DRAWN :19/03/2023 09:54:00 RECEIVED: 19/03/2023 12:04:44 REPORTED :26/03/2023 13:28:35

	i		
Test Report Status <u>Final</u>	Results	Biological Reference Inte	rval Units
BASOPHILS	00	0 - 2	%
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
ABSOLUTE NEUTROPHIL COUNT	2.41	2.0 - 7.0	thou/µL
METHOD: CALCULATED PARAMETER			
ABSOLUTE LYMPHOCYTE COUNT	1.55	1.0 - 3.0	thou/μL
METHOD: CALCULATED PARAMETER			
ABSOLUTE MONOCYTE COUNT	0.30	0.2 - 1.0	thou/μL
METHOD: CALCULATED PARAMETER			
ABSOLUTE EOSINOPHIL COUNT	0.04	0.02 - 0.50	thou/µL
METHOD: CALCULATED PARAMETER			
ABSOLUTE BASOPHIL COUNT	0 Low	0.02 - 0.10	thou/μL
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.6		

Interpretation(s)
BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Akansha Jain Consultant Pathologist





Page 2 Of 15

View Report



CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WC001794 PATIENT ID : ROSHF190393251

CLIENT PATIENT ID: 012303190031

ABHA NO

AGE/SEX :30 Years Female :19/03/2023 09:54:00 DRAWN RECEIVED: 19/03/2023 12:04:44

REPORTED :26/03/2023 13:28:35

Biological Reference Interval Test Report Status Results Units <u>Final</u>

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

E.S.R 0 - 20mm at 1 hr

METHOD: AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)"

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. **TEST INTERPRETATION**

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. Decreased in: Polycythermia vera, Sickle cell anemia

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia
False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, salicylates)

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

Dr. Akansha Jain Consultant Pathologist



Page 3 Of 15







CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WC001794 PATIENT ID : ROSHF190393251

CLIENT PATIENT ID: 012303190031

ABHA NO

AGE/SEX :30 Years Female DRAWN :19/03/2023 09:54:00 RECEIVED: 19/03/2023 12:04:44 REPORTED :26/03/2023 13:28:35

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE B

METHOD: TUBE AGGLUTINATION

POSITIVE RH TYPE

METHOD: TUBE AGGLUTINATION

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr. Akansha Jain **Consultant Pathologist**





Page 4 Of 15







CODE/NAME & ADDRESS : C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WC001794 PATIENT ID : ROSHF190393251

CLIENT PATIENT ID: 012303190031

ABHA NO

AGE/SEX :30 Years Female DRAWN :19/03/2023 09:54:00 RECEIVED: 19/03/2023 12:04:44 REPORTED :26/03/2023 13:28:35

Biological Reference Interval Units **Test Report Status** Results <u>Final</u>

_	•	$\overline{}$	\sim	-	 ~-	RY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR) 74 - 99 mg/dL 88

METHOD: GLUCOSE OXIDASE

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE **BLOOD**

HBA1C 5.3 Non-diabetic: < 5.7 %

> Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5Therapeutic goals: < 7.0 Action suggested: > 8.0 (ADA Guideline 2021)

METHOD: HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)

ESTIMATED AVERAGE GLUCOSE(EAG) 105.4 < 116.0 mg/dL

METHOD: CALCULATED PARAMETER

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR) 91 70 - 140 mg/dL

METHOD: GLUCOSE OXIDASE LIPID PROFILE, SERUM

METHOD: CHOLESTEROL OXIDASE

201 High < 200 Desirable CHOLESTEROL, TOTAL

mg/dL

200 - 239 Borderline High

>/= 240 High

TRIGLYCERIDES 45 < 150 Normal

mg/dL

150 - 199 Borderline High 200 - 499 High

>/=500 Very High

METHOD: LIPASE/GPO-PAP NO CORRECTION

78 High < 40 Low mg/dL HDL CHOLESTEROL

>/=60 High

METHOD: DIRECT CLEARANCE METHOD

Dr. Akansha Jain Consultant Pathologist





Page 5 Of 15







CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO : **0251WC001794**PATIENT ID : ROSHF190393251

CLIENT PATIENT ID: 012303190031

ABHA NO :

AGE/SEX :30 Years Female
DRAWN :19/03/2023 09:54:00
RECEIVED :19/03/2023 12:04:44
REPORTED :26/03/2023 13:28:35

Test Report Status <u>Final</u>	Results	Biological Reference Inter	val Units
CHOLESTEROL LDL	114 High	< 100 Optimal 100 - 129 Near optimal/ above optir 130 - 159 Borderline High 160 - 189 High >/= 190 Very High	mg/dL nal
NON HDL CHOLESTEROL	123	Desirable: Less than 130 Above Desirable: 130 - 15 Borderline High: 160 - 18 High: 190 - 219 Very high: > or = 220	_
METHOD: CALCULATED PARAMETER		, 3	
VERY LOW DENSITY LIPOPROTEIN	9.0	= 30.0</td <td>mg/dL</td>	mg/dL
CHOL/HDL RATIO	2.6 Low	3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk	
LDL/HDL RATIO	1.5	0.5 - 3.0 Desirable/Low R 3.1 - 6.0 Borderline/Mode Risk >6.0 High Risk	
Interpretation(s)			
LIVER FUNCTION PROFILE, SERUM			
BILIRUBIN, TOTAL METHOD: DIAZO WITH SULPHANILIC ACID	1.02 High	0 - 1	mg/dL
BILIRUBIN, DIRECT METHOD: DIAZO WITH SULPHANILIC ACID	0.34 High	0.00 - 0.25	mg/dL
BILIRUBIN, INDIRECT METHOD: CALCULATED PARAMETER	0.68	0.1 - 1.0	mg/dL
TOTAL PROTEIN METHOD: BIURET REACTION, END POINT	7.4	6.4 - 8.2	g/dL
ALBUMIN	4.6 High	3.8 - 4.4	g/dL

Dr. Akansha Jain



Page 6 Of 15

View Details



Consultant Pathologist







CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO : **0251WC001794**PATIENT ID : ROSHF190393251

CLIENT PATIENT ID: 012303190031

ABHA NO :

AGE/SEX :30 Years Female
DRAWN :19/03/2023 09:54:00
RECEIVED :19/03/2023 12:04:44
REPORTED :26/03/2023 13:28:35

Test Report Status <u>Final</u>	Results	Biological Reference In	terval Units
METHOD: BROMOCRESOL GREEN			
GLOBULIN	2.8	2.0 - 4.1	g/dL
METHOD : CALCULATED PARAMETER	2.0	2.0 - 4.1	g/ dL
ALBUMIN/GLOBULIN RATIO METHOD: CALCULATED PARAMETER	1.6	1.0 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE (AST/SGOT) METHOD: TRIS BUFFER NO P5P IFCC / SFBC 37° C	83 High	0 - 31	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD: TRIS BUFFER NO P5P IFCC / SFBC 37° C	75 High	0 - 31	U/L
ALKALINE PHOSPHATASE METHOD: AMP OPTIMISED TO IFCC 37° C	31 Low	39 - 117	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD: GAMMA GLUTAMYL-3 CARBOXY-4 NITROANILIDE (IFCC'	8) 37° C	7 - 32	U/L
LACTATE DEHYDROGENASE	480 High	230 - 460	U/L
BLOOD UREA NITROGEN (BUN), SERUM	_		
BLOOD UREA NITROGEN METHOD: UREASE KINETIC	8	5.0 - 18.0	mg/dL
CREATININE, SERUM			
CREATININE	0.93	0.6 - 1.2	mg/dL
METHOD: ALKALINE PICRATE NO DEPROTEINIZATION			
BUN/CREAT RATIO			
BUN/CREAT RATIO	8.60		
METHOD: CALCULATED PARAMETER			
URIC ACID, SERUM			
URIC ACID	4.0	2.4 - 5.7	mg/dL
METHOD: URICASE PEROXIDASE WITH ASCORBATE OXIDASE			
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN	7.4	6.4 - 8.3	g/dL
METHOD: BIURET REACTION, END POINT			
ALBUMIN, SERUM	4.6 High	2.0. 4.4	a/dl
ALBUMIN METHOD: BROMOCRESOL GREEN	4.6 High	3.8 - 4.4	g/dL
GLOBULIN			
GLOBULIN	2.8	2.0 - 4.1	g/dL

Dr. Akansha Jain Consultant Pathologist





Page 7 Of 15

View Report







CODE/NAME & ADDRESS : C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO : **0251WC001794**PATIENT ID : ROSHF190393251

CLIENT PATIENT ID: 012303190031

ABHA NO :

AGE/SEX :30 Years Female DRAWN :19/03/2023 09:54:00 RECEIVED :19/03/2023 12:04:44 REPORTED :26/03/2023 13:28:35

Test Report Status <u>Final</u>	Results	Biological Reference	ce Interval Units
ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM	144.4	137 - 145	mmo l /L
METHOD: ION-SELECTIVE ELECTRODE			
POTASSIUM, SERUM	4.27	3.6 - 5.0	mmo l /L
METHOD: ION-SELECTIVE ELECTRODE			
CHLORIDE, SERUM	103.8	98 - 107	mmo l /L
METHOD: ION-SELECTIVE ELECTRODE			

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis,	Decreased in: Low potassium	Decreased in: Vomiting, diarrhea,
vomiting, diarrhea, excessive	intake,prolonged vomiting or diarrhea,	renal failure combined with salt
sweating, salt-losing	RTA types I and II,	deprivation, over-treatment with
nephropathy, adrenal insufficiency,	hyperaldosteronism, Cushing's	diuretics, chronic respiratory acidosis
nephrotic syndrome, water	syndrome,osmotic diuresis (e.g.,	diabetic ketoacidosis, excessive
intoxication, SIADH. Drugs:	hyperglycemia),alkalosis, familial	sweating, SIADH, salt-losing
thiazides, diuretics, ACE inhibitors,	periodic paralysis,trauma	nephropathy, porphyria, expansion of
chlorpropamide,carbamazepine,anti	(transient).Drugs: Adrenergic agents,	extracellular fluid volume,
depressants (SSRI), antipsychotics.	diuretics.	adrenalinsufficiency,
		hyperaldosteronism, metabolic
		alkalosis. Drugs: chronic
		laxative,corticosteroids, diuretics.
Increased in: Dehydration	Increased in: Massive hemolysis,	Increased in: Renal failure, nephrotic
(excessivesweating, severe	severe tissue damage, rhabdomyolysis,	syndrome, RTA,dehydration,
vomiting or diarrhea),diabetes	acidosis, dehydration,renal failure,	overtreatment with
mellitus, diabetesinsipidus,	Addison's disease, RTA type IV,	saline,hyperparathyroidism, diabetes
hyperaldosteronism, inadequate	hyperkalemic familial periodic	insipidus, metabolic acidosis from
water intake. Drugs: steroids,	paralysis. Drugs: potassium salts,	diarrhea (Loss of HCO3-), respiratory
licorice, oral contraceptives.	potassium- sparing diuretics,NSAIDs,	alkalosis,hyperadrenocorticism.
	beta-blockers, ACE inhibitors, high-	Drugs: acetazolamide, androgens,
	dose trimethoprim-sulfamethoxazole.	hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or	Interferences: Hemolysis of sample,	Interferences:Test is helpful in
hyperproteinemi, if sodium analysis	delayed separation of serum,	assessing normal and increased anion
involves a dilution step can cause	prolonged fist clenching during blood	gap metabolic acidosis and in
spurious results. The serum sodium	drawing, and prolonged tourniquet	distinguishing hypercalcemia due to
falls about 1.6 mEq/L for each 100	placement. Very high WBC/PLT counts	hyperparathyroidism (high serum
mg/dL increase in blood glucose.	may cause spurious. Plasma potassium	chloride) from that due to malignancy
	levels are normal.	(Normal serum chloride)

Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Decreased in:Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease, malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency





Page 8 Of 15

View Report







CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

1ATPUR 302017 9314660100

ACCESSION NO: 0251WC001794 PATIENT ID : ROSHF190393251

CLIENT PATIENT ID: 012303190031

ABHA NO

AGE/SEX :30 Years Female DRAWN :19/03/2023 09:54:00 RECEIVED: 19/03/2023 12:04:44

REPORTED :26/03/2023 13:28:35

Test Report Status Results **Biological Reference Interval** Units **Final**

diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol;sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLYCOSYLATED HEMOGLOBIN (HBA1C), EDTA WHOLE BLOOD-**Used For**:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

- eAG gives an evaluation of blood glucose levels for the last couple of months.
 eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to :

- 1. Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days
- 2.Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.
 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

 4. Interference of hemoglobinopathies in HbA1c estimation is seen in
- a) Homozvoous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
- b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
- c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver,liver cancer,kidney failure,hemolytic anemia,pancreatitis,hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, is chemia to the liver, chronic

hepatitis, obstruction of bile ducts, cirrhosis. **ALP** is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease. **GGT** is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain

and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-Josing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome,protein-losing enteropathy,Burns,hemodilution,increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-**Causes of Increased** levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-**Higher than normal level** may be due to:

• Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such

Dr. Akansha Jain

Consultant Pathologist





Page 9 Of 15

View Report





CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WC001794 PATIENT ID : ROSHF190393251

CLIENT PATIENT ID: 012303190031

ABHA NO

AGE/SEX :30 Years Female DRAWN :19/03/2023 09:54:00 RECEIVED: 19/03/2023 12:04:44

REPORTED :26/03/2023 13:28:35

Results **Test Report Status Biological Reference Interval** Units <u>Final</u>

as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to: Myasthenia Gravis, Muscuophy
URIC ACID, SERUM-Causes of Increased levels: Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic

syndrome **Causes of decreased levels**-Low Zinc intake,OCP,Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin. **Higher-than-normal levels may be due to:** Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma,Waldenstroms disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. ALBUMIN, SERUM-

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr. Akansha Jain Consultant Pathologist



Page 10 Of 15









CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WC001794 PATIENT ID : ROSHF190393251

CLIENT PATIENT ID: 012303190031

ABHA NO

AGE/SEX :30 Years Female DRAWN :19/03/2023 09:54:00 RECEIVED: 19/03/2023 12:04:44 REPORTED :26/03/2023 13:28:35

Biological Reference Interval **Test Report Status** Results Units <u>Final</u>

CLINICAL PATH - URINALYSIS

CLEAR

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW **APPEARANCE**

CHEMICAL EXAMINATION, URINE

PH 5.5 4.7 - 7.51.003 - 1.035 SPECIFIC GRAVITY 1.020 **PROTEIN NOT DETECTED NOT DETECTED GLUCOSE** NOT DETECTED NOT DETECTED **KETONES NOT DETECTED NOT DETECTED BLOOD** NOT DETECTED NOT DETECTED **BILIRUBIN** NOT DETECTED NOT DETECTED **UROBILINOGEN NORMAL NORMAL NITRITE NOT DETECTED NOT DETECTED** LEUKOCYTE ESTERASE **NOT DETECTED NOT DETECTED**

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS NOT DETECTED NOT DETECTED /HPF 0-5 /HPF PUS CELL (WBC'S) 1-2 EPITHELIAL CELLS 3-5 0-5 /HPF

NOT DETECTED CASTS CRYSTALS NOT DETECTED

BACTERIA NOT DETECTED NOT DETECTED YEAST **NOT DETECTED NOT DETECTED**

Interpretation(s)

Dr. Akansha Jain Consultant Pathologist



Page 11 Of 15











CODE/NAME & ADDRESS : C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO : **0251WC001794**PATIENT ID : ROSHF190393251

CLIENT PATIENT ID: 012303190031

ABHA NO :

AGE/SEX :30 Years Female
DRAWN :19/03/2023 09:54:00
RECEIVED :19/03/2023 12:04:44
REPORTED :26/03/2023 13:28:35

Test Report Status Final Results Biological Reference Interval Units

CYTOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PAPANICOLAOU SMEAR

TEST METHOD

SAMPLE NOT RECEIVED

Dr. Akansha Jain Consultant Pathologist





Page 12 Of 15







REF. DOCTOR: SELF



PATIENT NAME: ROSHANI MEENA

CODE/NAME & ADDRESS : C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO : **0251WC001794**

PATIENT ID : ROSHF190393251

CLIENT PATIENT ID: 012303190031

ABHA NO :

AGE/SEX :30 Years Female
DRAWN :19/03/2023 09:54:00

RECEIVED : 19/03/2023 12:04:44 REPORTED : 26/03/2023 13:28:35

Test Report Status Final Results Biological Reference Interval Units

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, STOOL

COLOUR

METHOD: GROSS EXAMINATION

SAMPLE NOT RECEIVED

White the state of the state of

Dr. Abhishek Sharma Consultant Microbiologist





View Details

Niew Denam



Page 13 Of 15





REF. DOCTOR: SELF **PATIENT NAME: ROSHANI MEENA**

CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WC001794 PATIENT ID : ROSHF190393251

CLIENT PATIENT ID: 012303190031

ABHA NO

AGE/SEX :30 Years Female DRAWN :19/03/2023 09:54:00 RECEIVED: 19/03/2023 12:04:44 REPORTED: 26/03/2023 13:28:35

Test Report Status Results **Biological Reference Interval** Units **Final**

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

THYROID PANEL, SERUM

T3 101.34 60.0 - 181.0 ng/dL METHOD: CHEMILUMINESCENCE 7.00 4.5 - 10.9 µg/dL T4 METHOD: CHEMILUMINESCENCE 0.550 - 4.780μIU/mL

1.720

TSH (ULTRASENSITIVE) METHOD: CHEMILUMINESCENCE

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hypothyroidism, TSH levels are low. owidctlparowidctlparBelow mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism

Dr. Akansha Jain Consultant Pathologist



Page 14 Of 15









CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO : **0251WC001794**PATIENT ID : ROSHF190393251

CLIENT PATIENT ID: 012303190031

ABHA NO :

AGE/SEX :30 Years Female
DRAWN :19/03/2023 09:54:00
RECEIVED :19/03/2023 12:04:44
REPORTED :26/03/2023 13:28:35

Test Report Status <u>Final</u> Results Biological Reference Interval Units

8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. **NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.**TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

End Of Report
Please visit www.srlworld.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the SRL Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

SRL Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Dr. Akansha Jain Consultant Pathologist





Page 15 Of 15

